Inovio Pharma (INO)
$9.81
0.44 (4.66%)
INO Stock Quote Delayed 30 Minutes
Previous Close
-
Market Cap
891.99M
PE Ratio
-8.60
EPS
-1.14
Volume (Avg. Vol.)
16.40M
Day's Range
9.30 - 10.57
52-Week Range
3.14 - 33.79
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
Don’t Sleep on Inovio Pharmaceuticals as a Serious Vaccine Contender
When will INO stock finally turn a corner? That's a question on some investor's minds, and recent data suggests a turnaround might be afoot.
Reality Hits Home for Shares of Inovio Pharmaceuticals
Shares of INO stock is being held back by a delayed clinical trial for Inovio’s vaccine candidate to combat the coronavirus.
Just Say No to Inovio Pharmaceuticals Stock
While INO stock has boasted a banner year, Inovio appears no closer to a Covid-19 vaccine than any of the other 150 contenders.
Count on the Advancement of DNA Medicine with Inovio Stock
If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.
Prepare for Phase 2 and a Comeback for Inovio
Is INO stock nothing more than a post-pandemic pop-and-drop story? Don't count Inovio out as a crucial funding source offers timely support.
Inovio Gets the Go-Ahead But It’s Probably Too Late
Inovio got the go-ahead from the FDA on Nov. 16 to resume its Phase 2 clinical trial. Is INO stock worth betting on this late in the game?
Inovio Pharmaceutical’s FDA Plight Makes It a Highly Risky Bet
INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.
The Clock Is Ticking for Inovio Stock
The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.
Inovio Has Little to Show for Its Covid-19 Efforts
Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
At This Point, Go Ahead and Count Inovio Pharmaceuticals Out of the Vaccine Race
INO stock is a purely speculative bet. I don't see the company being among the few that deliver a vaccine against Covid-19.
Can Inovio Benefit From All Of Its Vaccine Delays?
Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase....
Avoid Taking a Bet on the Deep Correction In Inovio Stock
Small-cap biotechs are inherently challenging. With a failed INO-4800 timeline, INO stock increasingly finds itself back in this group.
Avoid Inovio Pharmaceuticals Stock Until the FDA Greenlights Trials
While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.
Inovio Investors Need FDA to Write Positive Prescription for Stock Gains
The bad news is that the FDA recently halted the Inovio trial. Think about that for a moment. The world is in dire of need of a Covid-19 vaccine and the U.S. is engaged “Operation Warp Speed” to get a vaccine to market, but here's a regulator telling Inovio to pump the brakes.
The FDA’s Questions Aren’t a Deal Breaker for Inovio Stock
INO stock is down but not out as the development of a Covid-19 vaccine is bound to have some bumps in the road.
Could the FDA Be Ready to Crash Inovio’s Hopes and Dreams?
It’s been a month since the FDA put Inovio’s Covid-19 vaccine on partial clinical hold. No news is definitely not good news for INO stock.
Time Is Running Out on Inovio as Other Vaccine Candidates Advance
The FDA's latest decision has dealt a killer blow to INO stock, which was already struggling to keep up with Big Pharma in the vaccine race.
Investors Should Buy the Phase II/III Dip in Inovio
INO stock is in a rough spot of late, but it is poised to bounce back from these temporary setbacks with a strong product portfolio.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
A
